2024-2030 China Stem Cell Industry Trend Analysis and Key Enterprise Research Report.
Publisher]: Zhongying Xinhe Research Network.
The content part has been deleted and detailed can be found in the full information published by Zhongying Xinhe Research Network! 】
Chapter 1 Overview of Stem Cells**.
1.1 Basic introduction to cells**.
1.1.1 The concept of cells**.
1.1.2 Classification of cells**.
1.2 Basic concepts of stem cells**.
1.2.1 Stem cell ** concept.
1.2.2 Stem cell industry.
1.2.3 Basic research on stem cells.
1.2.4 Stem cell mechanism.
1.3 Classification of stem cells.
1.3.1 Classification by developmental stage.
1.3.2 Classification by differentiation potential.
1.3.3 Other classifications of stem cells.
Chapter 2 2021-2023 development of the cell industry.
2.1 Analysis of China's cell** policy.
2.1.1 Summary of Cell** Policy Norms.
2.1.2 Cell** Policy Analysis.
2.1.3 Technical principles of cell ** products.
2.1.4 Cell** Application Management Measures.
2.1.5. Enter the industrial structure adjustment guidance catalog.
2.2 Cell** development.
2.2.1. The development stage of the cell industry.
2.2.2. The development situation of the cell industry.
2.2.3 Targets marketed at home and abroad.
2.2.4. The layout of the domestic cell industry chain.
2.2.5 Cell** Industry Typical Association.
2.2.6 Cell ** industry development issues.
2.2.7 Countermeasures for the development of the cell industry.
2.3 Development of clinical research on immune cells**.
2.3.1 Current status of clinical research on immune cells**.
2.3.2 Prospects for the clinical application of cell** types.
2.3.3 Development trend of immune cell application.
2.4. Cell** industrialization space.
2.4.1 Security Controls.
2.4.2 Effectiveness studies.
2.4.3 Cost control.
2.5 Outlook for the development trend of the cell industry.
2.5.1. Industry development advantages.
2.5.2 Industrial development opportunities.
2.5.3. Innovation agglomeration effect.
2.5.4 Product development trends.
Chapter 3 Analysis of the policy environment of China's stem cell industry.
3.1 Regulatory environment of China's stem cell industry.
3.1.1 Stem cell regulatory journey.
3.1.2 Regulatory body in the field of stem cells.
3.1.3 Stem cell regulatory pathways.
3.1.4 Stem cell storage specifications.
3.2 Analysis of China's stem cell ** policy.
3.2.1 Summary of stem cell ** policies.
3.2.2 Stem cell product guidelines.
3.2.3 Access to foreign investment in stem cells.
3.3 Regional stem cell** policy analysis.
3.3.1 Shanghai.
3.3.2 Chongqing Municipality.
3.3.3 Zhejiang Province.
3.3.4 Hebei Province.
Chapter 4 Analysis of the development of the stem cell industry from 2021 to 2023.
4.1. Stem cell industry chain composition.
4.1.1. Upstream of the industrial chain.
4.1.2. Midstream of the industrial chain.
4.1.3. Downstream of the industrial chain.
4.2 Global stem cell development**.
4.2.1 Development status of the global stem cell medical industry.
4.2.2 Globally registered stem cell clinical research projects.
4.2.3 Global Stem Cell** Drug Launch.
4.2.4 Global stem cell clinical patents.
4.3 China's stem cell market situation.
4.3.1 The development status of China's stem cell market.
4.3.2 The development scale of China's stem cell medical market.
4.3.3 Stem cell drugs approved for clinical trials in China.
4.4 Development of China's stem cell storage industry.
4.4.1 Basic introduction to stem cell storage.
4.4.2 Profit model of stem cell storage.
4.4.3. The scale of stem cell storage development.
4.4.4 Development of storage automation technology.
4.4.5. Construction of umbilical cord blood stem cell bank.
4.4.6 Prospects for the development of stem cell storage.
4.5 Clinical research on stem cells in China.
4.5.1 Stem cell clinical research institute.
4.5.2. Stem cell clinical research filing project.
4.5.3 Trends in the development of stem cell drugs.
4.6 Stem cell development problems and countermeasures.
4.6.1 Stem cell quality control standard issues.
4.6.2 Ethical review of stem cell research.
4.6.3 Construction of stem cell laws and regulations.
4.6.4 Analysis of regulatory countermeasures for stem cell research.
4.6.5 Suggestions for carrying out research on stem cell applications.
Chapter 5 Analysis of the development of mesenchymal stem cells** from 2021 to 2023.
5.1 Basic overview of mesenchymal stem cells.
5.1.1 Definition of mesenchymal stem cells.
5.1.2 Mesenchymal stem cell advantages.
5.1.3 Mesenchymal stem cell preparation process.
5.2 Global development of mesenchymal stem cells**.
5.2.1 Global mesenchymal stem cell clinical trials.
5.2.2 Global marketed drugs for mesenchymal stem cells.
5.2.3 Development of the mesenchymal stem cell industry in the United States.
5.3 Development of mesenchymal stem cells** in China.
5.3.1 Registration of mesenchymal stem cell clinical trials in China.
5.3.2 Mesenchymal stem cell clinical trial filing in China.
5.3.3 Mesenchymal stem cell drug approval dynamics in China.
5.4 Mesenchymal stem cells** challenges and countermeasures.
5.4.1 Clinical challenges of mesenchymal stem cells.
5.4.2 Clinical transformation of mesenchymal stem cells.
5.4.3 Clinical recommendations for mesenchymal stem cells.
Chapter 6 Analysis of the application of stem cell technology.
6.1 Stem cell** main technical analysis.
6.1.1 Stem cell purification technology.
6.1.2 Stem cell proliferation technology.
6.1.3 Stem cell differentiation technology.
6.2 Analysis of the application field of stem cells**.
6.2.1 Overview of the clinical application of stem cells**.
6.2.2 Advances in the field of diabetes with stem cells.
6.2.3 Advances in stem cells in the field of cardiology.
6.2.4 Stem cells in Alzheimer's disease research.
6.3 Research progress on the application of mesenchymal stem cells**.
6.3.1 Mesenchymal stem cells** spinal cord injury.
6.3.2 Mesenchymal stem cells** cartilage damage.
6.3.3 Mesenchymal stem cells** neurological diseases.
6.3.4. Mesenchymal stem cells** wound repair.
6.4 Mesenchymal stem cell research hotspot - novel coronavirus pneumonia**.
6.4.1 Immune pathogenesis of the new crown pneumonia virus.
6.4.2 Mesenchymal stem cells**Coronavirus mechanism.
6.4.3 Mesenchymal stem cells** new crown research progress.
6.4.4 Mesenchymal stem cells** new crown application prospects.
6.5 Research progress in the application of hematopoietic stem cells.
6.5.1 Characterization of hematopoietic stem cells.
6.5.2 Application of hematopoietic stem cell genes**.
6.5.3 Application of hematopoietic stem cell hematology**.
6.5.4 Application prospects of hematopoietic stem cells**.
6.6 Research progress on the application of epidermal stem cells.
6.6.1 Characterization of epidermal stem cells.
6.6.2 Epidermal stem cell signaling applications.
6.6.3 Wound healing of epidermal stem cells.
6.6.4 Anti-aging applications of epidermal stem cells.
6.7 Research progress on the application of umbilical cord mesenchymal stem cells.
6.7.1 Characterization of umbilical cord mesenchymal stem cells.
6.7.2 Umbilical cord mesenchymal stem cells** mechanism.
6.7.3 Umbilical cord mesenchymal stem cell transplantation**.
Chapter 7 Analysis of the development of key enterprises in the international stem cell industry from 2021 to 2023.
7.1 osiris therapeutics
7.1.1. Overview of enterprise development.
7.1.2 Analysis of business conditions in 2021.
7.1.3 Analysis of business conditions in 2022.
7.1.4 Analysis of business conditions in 2023.
7.2 seneca biopharma
7.2.1. Overview of enterprise development.
7.2.2 Analysis of business conditions in 2021.
7.2.3 Analysis of business conditions in 2022.
7.2.4 Analysis of business conditions in 2023.
7.3 mesoblast
7.3.1. Overview of enterprise development.
7.3.2 Analysis of business conditions in 2021.
7.3.3 Analysis of business conditions in 2022.
7.3.4 Analysis of business conditions in 2023.
7.4 CBM Biotechnology Group.
7.4.1. Overview of enterprise development.
7.4.2 Analysis of business conditions in 2021.
7.4.3 Analysis of business conditions in 2022.
7.4.4 Analysis of business conditions in 2023.
7.5 athersys
7.5.1. Overview of enterprise development.
7.5.2 Analysis of business conditions in 2021.
7.5.3 Analysis of business conditions in 2022.
7.5.4 Analysis of business conditions in 2023.
Chapter 8 Analysis of the operating conditions of key enterprises in China's stem cell industry from 2020 to 2023.
8.1 Guanhao Biotechnology Co., Ltd. ***
8.1.1. Overview of enterprise development.
8.1.2. Analysis of business benefits.
8.1.3 Business operation analysis.
8.1.4 Analysis of the financial situation.
8.1.5. Core competitiveness analysis.
8.1.6 The company's development strategy.
8.1.7 Future prospects.
8.2 Guangzhou Celera Stem Cell Technology Co., Ltd. ***
8.2.1. Overview of enterprise development.
8.2.2. Analysis of business benefits.
8.2.3 Business operation analysis.
8.2.4 Analysis of the financial situation.
8.2.5. Core competitiveness analysis.
8.2.6 The company's development strategy.
8.2.7 Future prospects.
8.3 Shunhao Cell Biotechnology (Tianjin) Co., Ltd. ***
8.3.1. Overview of enterprise development.
8.3.2. Analysis of business benefits.
8.3.3 Business operation analysis.
8.3.4 Analysis of the financial situation.
8.3.5. Core competitiveness analysis.
8.3.6 The company's development strategy.
8.3.7 Future prospects.
8.4 Zhongyuan Concord Cell Genetic Engineering Co., Ltd. ***
8.4.1. Overview of enterprise development.
8.4.2. Analysis of business benefits.
8.4.3 Business operation analysis.
8.4.4 Analysis of the financial situation.
8.4.5. Core competitiveness analysis.
8.4.6 The company's development strategy.
8.4.7 Future prospects.
Chapter 9 Analysis of the investment and financing status of the stem cell industry.
9.1. Investment and financing of stem cell industry.
9.1.1 Investment and financing status of stem cell industry.
9.1.2 Investment and financing dynamics of the stem cell industry.
9.1.3 Investment dynamics of stem cell industry projects.
9.2 Barriers to entry in the stem cell industry.
9.2.1 Technical barriers.
9.2.2. Talent barriers.
9.2.3 Financial barriers.
9.2.4 Regulatory barriers.
9.3 Investment risk analysis of stem cell industry.
9.3.1 Policy and regulatory risks.
9.3.2 Product R&D risks.
9.3.3 Risk of medical malpractice.
9.3.4 Brain drain risk.
9.3.5 Intellectual Property Risks.
9.3.6 The risk of intensified market competition.
Chapter 10 Zhongying Xinhe's analysis of the development trend and prospect of the stem cell industry.
10.1 Analysis of the development prospect of stem cell industry.
10.1.1 The development trend of the stem cell industry chain.
10.1.2 Trends in mesenchymal stem cell development.
10.1.3 Technological development trend of stem cell industry.
10.2 Zhongying Xinhe's analysis of China's stem cell industry from 2024 to 2030.
10.2.1 Analysis of influencing factors of China's stem cell industry from 2024 to 2030.
10.2.2 Market size of China's stem cell medical industry from 2024 to 2030**.
Table of Contents of Charts. Chart Cell ** classification.
Figure Schematic diagram of the differentiation "totipotency" of stem cells.
Figure Classification of stem cells by developmental stage
Figure Embryonic stem cells** and differentiation.
Figure Preparation of embryonic stem cells.
Figure Schematic diagram of adult stem cell differentiation.
Figure Diagram of hematopoietic stem cell differentiation.
Chart Hematopoietic stem cell + chemoradiotherapy combined**.
Figure Classification of stem cells by differentiation potential
Chart Number of clinical trials for gene and cell** drugs worldwide.
Figure 2015-2024 Global Gene and Cell** Market Size and Growth Rate.
Chart Innovative targeted drugs approved by the NMPA.
Chart: The core link of the gene ** industry chain.
Chart Stem cell industry chain.
Chart Distribution of downstream applications in the industrial chain.
Chart Global stem cell medical market size.
Chart Stem cell clinical research projects in major countries around the world.
Figure Annual distribution of articles related to stem cell research included in pubmed.
Chart Market size of China's stem cell medical industry.
Chart Stem cell drugs that have been implicitly licensed for clinical trials in China.
Diagram Umbilical cord blood hematopoietic stem cell bank with national license.
Chart The first batch of stem cell clinical research institutions to pass the record list.
Chart The second batch of stem cell clinical research filing institutions (1).
Figure The second batch of stem cell clinical research filing institutions (2).
Figure The second batch of stem cell clinical research filing institutions (3).
Chart 2019 New stem cell clinical research filing institutions.
Chart In 2020, new stem cell clinical research filing institutions were added.
Chart 2019 stem cell clinical research filing projects.
Chart 2020 stem cell clinical research filing projects.
Figure Mesenchymal stem cell drugs have been approved for marketing worldwide.
Chart Registration of clinical trials of mesenchymal stem cells in China.
Figure Mesenchymal stem cell clinical trial cells in China**.
Chart Main indications for mesenchymal stem cell clinical trials in China.
Figure Dosing route of mesenchymal stem cell clinical trial in China.
Figure Mesenchymal stem cell clinical research project in China**.
Chart Types of diseases with stem cells**.
Figure Mesenchymal stem cells**Refractory wounds.
Chart Osiris Therapeutics' main stem cell products.
Chart 2020-2021 Osiris Therapeutics Comprehensive Income Statement.
Chart 2020-2021 Osiris Therapeutics segment data.
Chart 2020-2021 Osiris Therapeutics Revenue by Region.
Chart 2021-2022 Osiris Therapeutics Comprehensive Income Statement.
Chart 2021-2022 Osiris Therapeutics segment data.
Chart 2021-2022 Osiris Therapeutics Revenue by Region.
Chart 2022-2023 Osiris Therapeutics Comprehensive Income Statement.
Chart 2022-2023 Osiris Therapeutics segment data.
Chart Seneca Biopharma Comprehensive Income Statement, 2020-2021.
Chart 2020-2021 Seneca Biopharma Segment Data.
Chart 2020-2021 Seneca Biopharma Revenue by Region.
Chart Seneca Biopharma Comprehensive Income Statement, 2021-2022.
Chart 2021-2022 Seneca Biopharma Segment Data.
Chart 2021-2022 Seneca Biopharma Revenue by Region.
Chart 2022-2023 Seneca Biopharma Comprehensive Income Statement.
Chart 2022-2023 Seneca Biopharma segment data.
Chart Mesoblast Comprehensive Income Statement, 2020-2021.
Chart 2020-2021 Mesoblast Segment Data.
Chart 2020-2021 Mesoblast Revenue by Region.
Chart Mesoblast Comprehensive Income Statement 2021-2022.
Chart 2021-2022 Mesoblast Segment Data.
Chart Mesoblast Revenue by Region, 2021-2022.
Chart Mesoblast Comprehensive Income Statement 2022-2023.
Chart 2022-2023 Mesoblast Segment Data.
Chart 2020-2021 Cellular Biomedicine Group Comprehensive Income Statement.
Chart 2020-2021 Cellular Biomedicine Group segment data.
Chart Cellular Biomedicine Group Revenue by Region, 2020-2021.
Chart 2021-2022 Cellular Biomedicine Group Comprehensive Income Statement.
Chart 2021-2022 Cellular Biomedicine Group segment data.
Chart 2021-2022 Cellular Biomedicine Group Revenue by Region.
Chart 2022-2023 Cellular Biomedicine Group Comprehensive Income Statement.
Chart 2022-2023 Cellular Biomedicine Group segment data.
Chart 2020-2021 Athersys Comprehensive Income Statement.
Chart 2020-2021 athersys segment data.
Chart 2020-2021 athersys revenue by region.
Chart 2021-2022 Athersys Comprehensive Income Statement.
Chart 2021-2022 Athersys segment data.
Chart 2021-2022 Athersys Revenue by Region.
Chart 2022-2023 Athersys Comprehensive Income Statement.
Chart 2022-2023 Athersys segment data.
Chart 2020-2023 total assets and net assets of Guanhao Biotechnology Co., Ltd.
Chart 2020-2023 Guanhao Biotechnology Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 net profit and growth rate of Guanhao Biotechnology Co., Ltd.
Chart 2022 Guanhao Biotechnology Co., Ltd.***Main business by industry.
Chart 2022 Guanhao Biotechnology Co., Ltd.*** main business by region.
Chart 2020-2023 Guanhao Biotechnology Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 return on net assets of Guanhao Biotechnology shares.
Chart 2020-2023 Guanhao Biotechnology shares*** short-term solvency indicators.
Chart 2020-2023 Guanhao Biotechnology shares*** asset-liability ratio level.
Chart 2020-2023 Guanhao Biotechnology Co., Ltd. *** operating capacity indicators.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd.*** total assets and net assets scale.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd. *** net profit and growth rate.
Chart 2022 Guangzhou Celera Stem Cell Technology Co., Ltd.*** main business by industry.
Chart 2022 Guangzhou Celera Stem Cell Technology Co., Ltd.***Main business by region.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd. *** return on net assets.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd. *** short-term solvency index.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd.*** asset-liability ratio level.
Chart 2020-2023 Guangzhou Celera Stem Cell Technology Co., Ltd. *** operating capacity indicators.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd.*** total assets and net assets.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd. *** net profit and growth rate.
Chart In 2022, Shunhao Cell Biotechnology (Tianjin) Co., Ltd.*** main business is divided into industries.
Chart 2022 Shunhao Cell Biotechnology (Tianjin) Co., Ltd.*** main business by region.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) shares *** return on net assets.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd. *** short-term solvency index.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd.*** asset-liability ratio level.
Chart 2020-2023 Shunhao Cell Biotechnology (Tianjin) Co., Ltd.'s operational capacity indicators.
Chart 2020-2023 total assets and net assets of Zhongyuan Concord Cell Genetic Engineering Co., Ltd.
Chart 2020-2023 Zhongyuan Concord Cell Genetic Engineering Co., Ltd.*** operating income and growth rate.
Chart 2020-2023 net profit and growth rate of Zhongyuan Concord Cell Genetic Engineering Co., Ltd.
Chart 2022 Zhongyuan Concord Cell Genetic Engineering Co., Ltd.***Main business by industry.
Chart 2022 Zhongyuan Concord Cell Genetic Engineering Co., Ltd.*** main business by region.
Chart 2020-2023 Zhongyuan Concord Cell Genetic Engineering Co., Ltd.*** operating profit and operating profit margin.
Chart 2020-2023 return on net assets of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Chart 2020-2023 Short-term solvency index of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Chart 2020-2023 Asset-liability ratio level of Zhongyuan Concord Cell Genetic Engineering Co., Ltd.
Chart 2020-2023 Zhongyuan Concord Cell Genetic Engineering Co., Ltd. *** operating capacity index.
Chart Investment and financing of stem cell industry from 2015 to 2020.
Chart: The market size of China's stem cell medical industry from 2024 to 2030**.